Clover Health Investments is trading lower Tuesday afternoon after the Trump administration proposed flat MA payment rates for 2027.

Clover Health Investments is now a contrarian buy, with the market underestimating its path to profitability in 2026. See why I rate the CLOV stock a Buy.

Clover Health Investments CLOV is well poised for growth in the coming quarters, courtesy of its broad product spectrum. This ...

Clover Health Investments recently reported that its Medicare Advantage membership grew about 53% year over year to roughly ...

Clover Health Investments Corp (NASDAQ: CLOV) stock is rising Wednesday after the company announced that it expects to ...

Clover Health Investments (CLOV) drew fresh attention after reporting a 53% year-over-year jump in Medicare Advantage PPO ...

We came across a bullish thesis on Clover Health Investments, Corp. on topsecretstocks’s Substack. In this article, we will ...

Clover Health Investments, Corp. announced that its Chief Financial Officer, Peter Kuipers, will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 11:00 a.m. ET, ...

Clover Health Investments shares rose after the company said it expected to turn a profit in 2026 following a strong Medicare Advantage enrollment period. Shares were up 11% to $2.82 in Wednesday ...

Okay. All right. Thanks for joining us here today. With us today, we have Clover Health. On stage is CFO, Peter Kuipers. I believe he's going to start off with the presentation. Thank you, Jonathan.